Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Calidi Biotherapeutics ( (CLDI) ) is now available.
Calidi Biotherapeutics, Inc. has entered into a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. to sell 5,000,000 shares of its common stock at $0.85 per share in a public offering, expected to close on January 10, 2025. This offering is projected to generate gross proceeds of $4.25 million. The agreement includes restrictions on further stock issuance for a specified period and involves lock-up agreements for company insiders. The Placement Agent will receive an 8% cash fee and a 1% management fee from the proceeds, along with warrants for additional shares. The offering aligns with the company’s strategy to strengthen its financial position within the market.
More about Calidi Biotherapeutics
YTD Price Performance: 14.41%
Average Trading Volume: 1,797,447
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $25.44M
For an in-depth examination of CLDI stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue